BioAge Labs, Inc. (BIOA) Stock Price & Analysis
BioAge Labs, Inc. (BIOA) closed at USD 5.35 on Thursday, October 15, 2026, down 1.29% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 5.42; the Oct 15, 2026 session ranged USD 5.28–5.5 on volume of 811,314 shares. Market capitalization is $245.55M, with a 52-week range of USD 5.04–25.96 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BIOA.md
Key facts (BIOA)
- Last four reported quarters (through Jun 30, 2026): revenue $10.4M, net income -$94.5M (-912.3% margin), free cash flow -$88.1M (SEC filings).
- Analysts: Buy (mean 2.10 on a 1–5 scale) (10 analysts), mean target USD 32.56 (range 8–73).
- Total return with dividends: 1Y +4.7% vs S&P 500 +18.1%; 5Y -74.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.63, revenue estimate $1.5M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BIOA)
| USD | FY2024 | FY2025 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | — | $0K | $9.0M | $10.4M |
| Operating income | -$48.4M | -$78.2M | -$92.8M | -$106M |
| Net income | -$63.9M | -$71.1M | -$80.6M | -$94.5M |
| EPS (diluted) | -$38.17 | -$6.63 | -$2.24 | — |
| Free cash flow | -$37.5M | -$51.9M | -$82.3M | -$88.1M |
| Operating margin | — | — | -1031.5% | -1026.3% |
| Net margin | — | — | -896.1% | -912.3% |
| Cash + short-term investments | $21.6M | $354M | $281M | — |
| Total debt | $14.2M | $8.5M | $2.6M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BIOA)
P/S 23.7x · P/B 0.7x · FCF yield -35.87% · Earnings yield -38.47%
Analysts (BIOA)
Consensus Buy (mean 2.10 on a 1–5 scale), 10 analysts; mean target USD 32.56 (low 8, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiated | Neutral | $8 |
| 2026-09-09 | Roth Capital | Reiterated | Buy | $25 |
| 2026-09-08 | BTIG | Reiterated | Buy | $40 |
| 2026-08-06 | BTIG | Reiterated | Buy | $40 |
| 2026-08-03 | BTIG | Reiterated | Buy | $40 |
| 2026-07-31 | Needham | Target lowered | Buy | $50 → $35 |
Total return (dividends reinvested) (BIOA)
| 1Y (from 2025-10-16) | 5Y (from 2024-09-23) | |
|---|---|---|
| Total return | +4.7% | -74.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +4.7% | -48.5% |
| Volatility (annualized) | 132.4% | 144.5% |
| Max drawdown | -78.7% (Jul 2026→Oct 2026) | -86.3% (Oct 2024→Mar 2025) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 5.35 |
|---|---|
| Change | ▼ 1.29% (down) |
| Previous Close | USD 5.42 |
| Open | USD 5.48 |
| Day Range | USD 5.28 – 5.5 |
| 52-Week Range | USD 5.04 – 25.96 |
| Volume | 811,314 shares |
| Market Cap | $245.55M |
| Exchange | NMS |
Technical Analysis (BIOA)
Nexqual's technical model rates BIOA "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 15.12 (oversold) |
| vs SMA50 | Below (USD 8.56) |
| MACD | -1.04 (negative) |
Analyst Ratings (BIOA)
Wall Street analysts rate BIOA "Buy" based on 10 analysts, with a mean price target of USD 32.56 (range USD 8–73), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 32.56 |
| High Target | USD 73 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 7 / 3 / 0 |
Earnings (BIOA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.63 |
| Revenue Estimate | $1.48M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.58 vs est -0.62 ▲ beat |
| 2026-03-31 | USD -0.52 vs est -0.63 ▲ beat |
| 2025-12-31 | USD -0.72 vs est -0.67 ▼ miss |
| 2025-09-30 | USD -0.56 vs est -0.51 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (BIOA)
| Total Revenue | $10.36M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.60% |
| Gross Margin | +0.00% |
| Operating Margin | -1196.78% |
| Profit Margin | +0.00% |
| ROE | -28.21% |
| Debt / Equity | 0.01 |
| Current Ratio | 17.19 |
| Total Cash | $318.74M |
| Total Debt | $2.83M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$82.35M (-915.5% of revenue) |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (BIOA)
Nexqual rates BioAge Labs, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — Revenue +1.6% YoY (latest Q), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $319M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$82M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -28%, ROA -18.5% |
Ownership (BIOA)
| Insider Ownership | +2.36% |
|---|---|
| Institutional Ownership | +90.61% |
| Shares Outstanding | 45.90M |
| Float | 39.19M |
| Short % of Float | +8.03% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (BIOA)
BioAge Labs, Inc. is led by Kristen Fortney (age 41), Co-Founder, CEO, President, Treasurer, Secretary & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| Co-Founder, CEO, President, Treasurer, Secretary & Director | Kristen Fortney (age 41) |
|---|---|
| Co-Founder, COO & Director | Eric Morgen (age 42) |
| Chief Financial Officer | Dov A. Goldstein (age 58) |
| Senior Vice President of Finance & Accounting | Shane Barton (age 54) |
| Senior Vice President of Research | Rusty Montgomery |
Major Backers & Investors (BIOA)
Notable institutional backers of BioAge Labs, Inc. include a16z Capital Management, L.L.C., Cormorant Asset Management, LP, Sofinnova Investments, Inc., according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| a16z Capital Management, L.L.C. | 7.04% |
| Cormorant Asset Management, LP | 5.21% |
| Sofinnova Investments, Inc. | 5% |
| Jupiter Topco LLC | 4.67% |
| Octagon Capital Advisors LP | 3.81% |
| RA Capital Management, L.P. | 3.64% |
| MPM Bioimpact LLC | 3.63% |
| Polar Capital Holdings PLC | 2.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.32% |
| Vanguard Group | 6.65% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 39.57 | ▼ 5.81% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt